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To compare the dosimetrical differences between plans generated by helical tomotherapy using 2D 
or 3D margining technique in in prostate cancer. Ten prostate cancer patients were included in this 
study. For 2D plans, planning target volume (PTV) was created by adding 5 mm (lateral/anterior-
posterior) to clinical target volume (CTV). For 3D plans, 5 mm margin was added not only in 
lateral/anterior-posterior, but also in superior-inferior to CTV. Various dosimetrical indices, including 
the prescription isodose to target volume (PITV) ratio, conformity index (CI), homogeneity index (HI), 
target coverage index (TCI), modified dose homogeneity index (MHI), conformation number (CN), 
critical organ scoring index (COSI), and quality factor (QF) were determined to compare the different 
treatment plans.  
Differences between 2D and 3D PTV indices were not significant except for CI (p = 0.023). 3D 
margin plans (11195 MUs) resulted in higher (13.0%) monitor units than 2D margin plans (9728 MUs). 
There were no significant differences in any OARs between the 2D and 3D plans. Overall, the average 
2D plan dose was slightly lower than the 3D plan dose. Compared to the 2D plan, the 3D plan 
increased average treatment time by 1.5 minutes; however, this difference was not statistically 
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significant (p = 0.082). We confirmed that 2D and 3D margin plans are not significantly different with 
regard to various dosimetric indices such as PITV, CI, and HI for PTV, and OARs with tomotherapy.  
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I. INTRODUCTION 
Prostate cancer is the sixth most common cancer in the world, and 85% of cases are diagnosed in 
men older 65 years [1]. In men with well to moderately-differentiated prostate cancer that remains 
encapsulated, the clinical progression-free survival rates are 70% and 40% at 5 and 10 years, 
respectively. In recent years, radiotherapy has been an alternative to radical prostatectomy for localized 
prostate cancer, as well as the preferred treatment for both locally advanced cases and those in elderly 
patients [2]. The advent of intensity-modulated radiation therapy (IMRT) has enabled the delivery of 
highly conformed dose distributions to target volumes in the prostate [3-6]. Helical tomotherapy (HT) 
is an IMRT delivery technique that provides both highly conformed therapeutic doses as well as image-
guidance via megavoltage-computed tomography [7-9]. Dose conformity is critical in radiation therapy 
since it offers the opportunity to accurately deliver the desired radiation doses to the desired target 
volume while sparing the nearby healthy organs during treatment.              
In practice, however, even HT treatments may be delivered to tissues outside of the prescribed 
clinical target volume (CTV) due to daily setup uncertainties and changes in patient anatomical 
structures, especially in cases of prostate [10, 11]. Daily setup uncertainties are typically managed by 
implementing procedures that reduce setup error; for example, in prostate radiotherapy, a variety of 
clinical methods is routinely used to manage prostate motion during external beam radiotherapy. These 
methods include skin marks matched to in-room lasers, weekly or daily ports of the pelvic bony 
anatomy, trans-abdominal ultrasonography, computed tomography (CT) on rails, intra-prostatic gold 
seeds visualized with an electronic portal imaging device, and radiofrequency transponders [12-15]. 
However, since the patient’s external position has a limited ability to predict the internal anatomical 
positions, even with the careful use of these immobilization devices, the target’s position may vary 
from day to day [16, 17]. Furthermore, patients often show notable anatomical changes over the course 
of treatment due to tumor regression and weight loss, which create relative non-rigidity between 
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individual structures and lead to additional setup error [18, 19].  
To account for these setup uncertainties and ensure that a sufficient dose is delivered to the target, 
treatment planners apply safety margins to the CTV. In clinical applications, both 2 and 3 dimensional 
(D) automatic margining algorithms can be used to expand the CTV with a constant margin in each of 
6 possible directions (left [L], right [R], anterior [A], posterior [P], superior [S], and inferior [I]). The 
mathematical basis for automatic margining tools is morphological dilation, the equations for which 
have been discussed elsewhere [20-22]. Methods used by the original 3D automatic margining tools for 
radiotherapy planning were reported over a decade ago, and their superiority over 2D margining tools 
and manual planning target volume (PTV) outlining has been discussed [23, 24]. Researchers 
compared the margining algorithms in commercial treatment planning systems and found significant 
differences in the 3D margining algorithms of treatment planning systems [25, 26]. 
However, differences in the automatic 2D and 3D margining methods with regard to planning 
aspects for HT are not clearly established. The difference in the longitudinal direction could be more 
significant than in other directions in HT because of the helical treatment method. Here, we compare 
the dosimetric results of the 2D and 3D automatic margining methods in HT to determine the optimized 
automatic margining technique for prostate cancer.  
II. Materials and Methods 
A. Patient characteristics 
Ten patients previously treated for prostate cancer with HT were selected for this study. The 
characteristics of these 10 patients are described in Table 1. The patients presented with a variety of 
stages (stage I to stage III) and target sizes (PTV from 43.7 cm3 to 140.4 cm3). All patients manifested 
relatively good performance statuses, and none of the treatment areas involved lymph nodes (Table. 1). 
B. CT simulation 
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The CTV and organs at risk (OARs) were contoured on simulation CT (Philips Medical System, 
Eindhoven, The Netherlands) images (in-slice spatial resolution, 512 × 512 mm3 and slice interval, 3 
mm) for treatment planning. All CT data were transferred to the treatment planning system (TPS, 
Eclipse version 8.9, Varian Medical System Inc., Palo Alto CA, USA). 
C. Treatment planning 
A total of 20 plans, 2 per patient, were generated to compare the differences between 2D and 3D 
margining algorithms in this study. The planning techniques and plan parameters for the 2D and 3D 
algorithms were the same for all patients. After contouring all PTVs and OARs in TPS, the planning 
CT data with radiation therapy structures were transferred from Eclipse TPS to Pinnacle TPS, and the 
CT data were imported into the TomoTherapy Planning station (Hi-Art version 4.2.1, Accuray Inc., 
Madison, WI, USA) for tomotherapy IMRT planning. 
In the tomotherapy planning system, we added 5-mm margins to CTV in both the 2D and 3D 
algorithms for each patient, designated PTV-2D and PTV-3D, so that the margin for each PTV was 
created automatically from both the 2D and 3D margin algorithms, as shown in Fig. 1. The same 
process was applied to the OARs. In some cases where the OARs overlapped with the PTVs, the OAR 
volumes were set to the volume that initial OARs substrate the initial PTVs. 
All plans were prescribed as 95% PTV receiving 70Gy doses. Tomotherapy plan optimization was 
performed by a medical physicist according to our protocol. For all plans, the field width, pitch, and 
modulation factor values were 1.05, 0.287, and 2.5 cm, respectively. Iterations were performed 200 
times to satisfy the PTV coverage and OAR tolerance dose levels. The following OARs were defined: 
bladder, rectum, femoral head, bone marrow, hip joint, and urethra. OAR dose constraints were set 
according to Emami [27], QUANTEC [28], and RTOG [29]data (Table. 2). 
D. Treatment plan analysis 
Several quantitative evaluation tools were used to compare the 20 tomotherapy plans with one 
another. These included the prescription isodose to target volume (PITV) ratio, homogeneity index (HI), 
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conformity index (CI), target coverage index (TCI), modified dose homogeneity index (MHI), 
conformity number (CN) for the PTV, maximum dose, mean dose, the dose volume histogram (DVH), 
and the critical organ scoring index (COSI) for the OAR. PITV ratio was obtained by dividing the 
prescription isodose surface volume by the target volume [30]. CI, defined as the ratio of the target 
volume and the volume inside the isodose surface that corresponds with the prescription dose, is 
generally used to indicate the portion of the prescription dose that is delivered inside the PTV [31]. HI 
is the ratio of the maximum dose delivered to the PTV and the prescription dose to the PTV [32]. TCI 
refers to the exact coverage of the PTV in a treatment plan for a given prescription dose. The MHI is 
similar to the HI, expressed as 95% dose coverage divided by 5% dose coverage [32]. Conformity 
number (CN) refers to the relative measurement of the dosimetric target coverage and the sparing of 
normal tissues in a treatment plan [33]. The CN is expressed as:  
CN = TCI × CI =
𝑃𝑇𝑉𝑃𝐷
𝑃𝑇𝑉
×
𝑃𝑇𝑉𝑃𝐷
𝑃𝐼𝑉
           (1) 
where PTVPD refers to the PTV coverage at the prescription dose and PIV represents the prescription 
isodose surface volume. COSI index takes into account both the target coverage and the critical organ 
irradiation; the main advantage of this index is its ability to distinguish between different critical organs 
[34].  The COSI is expressed as: 
COSI = 1 −  ∑ 𝑤𝑖
𝑛
1
𝑉𝑖(𝑂𝐴𝑅)>𝑡𝑜𝑙
𝑇𝐶
              (2) 
where V(OAR)>tol is the fraction of the volume of the OAR that receives more than a pre-defined 
tolerance dose, and TCV is the volumetric target coverage, which is defined as the fractional volume of 
PTV covered by the prescribed isodose. Here, we introduce a dosimetrical index, which may be used to 
evaluate whole-plan quality, which we refer to as quality factor (QF). The QF of a plan can be 
analytically expressed as: 
QF =  [2.718 exp(− ∑ 𝑊𝑖𝑋𝑖
𝑁
𝑖=1 )]            (3) 
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 In the above equation, Xi represents all of the PTV indices used in this study, including PITV, CI, HI, 
TCI, MHI, CN, and COSI. The values of the weight factor (Wi) can be adjusted between 0 and 1 for all 
relatively weighted indices for a user-defined number of indices (N). In this study, we used a weighting 
factor of 1 for all separate indices. Thus, QF was mainly used to compare the conformity of plans in the 
various trials of a treatment [35]. 
We used maximum dose, mean dose, and DVHs to quantitatively evaluate the dose distributions in 
the rectum and bladder. The DVH index employed in our study included V5, V10, V20, V30, V40, V50, 
V60, and V70. A time factor, including the planning time and treatment time, was also included in our 
study to show treatment and clinical efficacy. In addition, the planning time included the optimization 
time, and treatment time represented the total treatment time. 
E. Statistical analysis 
Data are reported as means ± SDs. To determine whether the differences between dosimetrical and 
biological indices were significant, the Kruskal-Wallis test and the Mann-Whitney test were performed. 
All calculations were performed using SPSS software, version 19.0. Differences were considered 
significant for p values < 0.05. 
III. Results 
A. PTV 
Isodose distributions of the axial (a, b), coronal (c, d), and sagittal (e, f) for the 2D (left column) and 
3D (right column) margin plans are shown in Fig. 2. The orange, cyan, and blue in the PTV indicate 
color wash areas of 95% (66.5Gy), 50% (35Gy), and, 30% (21Gy), respectively. In a 3-plane 
comparison (axial, coronal, and sagittal), the 2D and 3D margin plans showed no significant 
differences in PTV volume isodose distributions. However, when the 3D margin algorithm was applied 
to the PTV volume, the volume was slightly larger than when the 2D margin algorithm was applied 
(Fig. 2 c, d). Additionally, DVHs of respective 2D and 3D margin plans were showed in Fig. 3. The 
 8 
results of the dosimetric comparisons of the PTV indices (PITV, CI, HI, TCI, MHI, CN) indicated that 
most of these indices were better in 3D margining plans than in the 2D plans (Table. 3). Only CI 
showed a statistically significant difference (p = 0.023). PTV monitor units (MUs) were higher in the 
3D margining plan than in the 2D plan (Table. 4), although this difference was not statistically 
significant (p = 0.076). The 3D margin plan (11195 MUs) increased the MUs by 13.0% compared to 
2D margin (9728 MUs). This difference might be due to PTV volume differences between the 2D and 
3D margin plans. 
B. OAR 
The average OAR doses in the 10 patients are shown in Table. 5, and the DVHs are shown in Fig. 3. 
The OARs did not differ significantly between the 2D and 3D margin plans. However, the overall 
average dose in the 2D margin plan was slightly lower than that in the 3D margin plan. This difference 
was indicated by the COSI values (2D margining plan, 0.9254 ± 0.0603; 2D margining plan, 0.8614 ± 
0.1520) 
C. Treatment time 
The treatment times of both margining plans are shown in Table. 4. Compared to the 2D margin plan, 
the 3D margin plan increased the average treatment time by 1.5 minutes; however, this difference was 
not statistically significant (p = 0.082). 
D. QF 
The QF results did not differ significantly between the 2D and 3D plans (Table. 4), although the QF 
of the 2D plans was higher than that of the 3D plans. (Table 3). 
 
IV. Discussion 
As reported in The International Commission on Radiation Units and Measurements (ICRU) Report 
50, the 3D radiation treatment plan technique has become important in radiation therapy [36]. Thus, a 
study on the appropriate tumor and OAR margins is important with respect to the extent of tumor 
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contouring, the magnitude of patient and organ motion, and treatment setup error [24, 37]. In this paper, 
therefore, we compared dosimetric results of the 2D and 3D automatic margining HT methods to 
determine the optimized automatic margining technique for prostate cancer.  
The results of this study confirmed that the isodose line of the 3D margin plan gave a larger volume 
in the axial view than that of the 2D margin plan (Fig. 1 (e)). We showed that the PTV volume for the 
3D margin was particularly larger in coronal view (Fig. 2 (c) and (d)). This is because the 2D algorithm 
plans were created by excluding the superior and inferior direction margins, while the longitudinal 
direction margin was considered for the 3D margin plan. We confirmed that the 2D margin algorithm 
had an inherent discrepancy, and the adequate margin algorithm was obtained with the 3D margin 
method, which did not give a deficient PTV volume. However, the dosimetric results did not differ 
significantly between the 2 plans according to volume changes in a comparison of dosimetric indices 
(Table. 3). Although the reason for this is not exactly clear, we thought that this was because in the 
cases selected were regularly shaped. 
The DVHs of the 2 margin algorithm plans appeared to be similar in all OARs (Figure 3). 
Statistically significant differences were not observed between the 2 methods (Table. 5). However, the 
2D margin algorithm plan dose was smaller than that of the 3D margin plan for the low-dose region 
from V5 to V 20 due to the above-described volume deficiency of the inherent 2D margin algorithm. 
Our results are consistent with those of the study conducted by Khoo et al. [24], which found that the 
2D margin algorithm had a volume deficiency. The deficient volume was an important problem 
because the PTV and OARs can be underestimated. This could possibly reduce the target coverage and 
the OAR volume changes. Additionally, this could potentially decrease the likelihood of tumor control 
and increase the risk of normal tissue complications. Therefore, it is necessary to select an adequate 
margin algorithm to improve the therapeutic ratio.  
Several issues warrant further investigation. In this study, we selected prostate cancer cases with 
relatively regular tumor shapes. Volume differences between the 2D and 3D margin algorithms due to 
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tumor shape are expected, and thus, we are planning to compare regularly and irregularly shaped 
tumors. Additionally, further studies are needed to investigate different cases and thus compare the 
results of this study with those of other cases. 
All plans were dosimetrically acceptable (±3%) with regard to target coverage and dose 
homogeneity, and all critical structures were within the tolerance range. The QF results showed that the 
combination of smaller field widths and higher pitches might be an important factor for achieving 
optimized treatment planning parameters. However, it is important to consider time factors for clinical 
application because smaller field widths can result in longer optimization and treatment times. 
III. CONCLUSION 
We confirmed that 2D and 3D margin plans are not significantly different with regard to various 
dosimetric indices such as PITV, CI, and HI for PTV, and OARs with tomotherapy. To evaluate the 
optimization plan margin method, we confirmed the feasibility of using QF index. We are planning to 
investigate the weighted value of each index to improve the accuracy of QF. 
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Table 1. Characteristics of the patients and tumors.  
Number   10 
Age (years) <70 4 
 
>70 6 
T stage T1 2 
 
T2 6 
 
T3 2 
N stage N0 10 
 
N1 0 
M stage M0 10 
 
M1 0 
Grade I 2 
 
II 6 
 
III 2 
Gleason score 6 4 
 
7 1 
 
8 5 
PTV (cc) 
 
99.06 
Rectum (cc) 
 
68.38 
Bladder (cc) 
 
137.63 
Hip joint (cc) 
 
30.19 
Bone marrow (cc)   462.61 
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Table 2. Normal organ tolerance dose.  
QUANTEC* Data EMAMI
¶
 Data 
Critical  
structure 
Dose(Gy)/ 
Volume(%) 
Toxicity rate 
Toxicity  
endpoint Notes
‡
  
TD
5/5
 
Whole  2/3  1/3 
Rectum 
V
50
 <50% 
<10% 
Grade  
3+  
toxicity 
Prostate  
cancer  
treatment  
3D-CRT 
6000 
– – 
V
60
 <35% – – 
V
65
 <25% – – 
V
70
 <20% – – 
V
75
<15% – – 
Bladder 
V
65
<50% – 
Grade  
3+  
toxicity 
Prostate  
cancer  
treatment  
(RTOG)  
0415  
recommendation  
3D-CRT 
6500 8000 
N/A 
V
70
<35% – – 
V
75
<25% – – 
V
80
<15% – – 
Abbreviations: 3D-CRT = 3-dimensional conformal radiotherapy, RTOG = Radiation Therapy Oncology Group. 
* All data are estimated from the literature summarized in the QUANTEC reviews unless otherwise noted. Clinically, these data should be 
applied with caution. Clinicians are strongly advised to use the individual QUANTEC articles to check the applicability of these limits to the 
clinical situation at hand. They largely do not reflect modern IMRT. 
‡ All at standard fractionation (i.e., 1.8–2.0 Gy per daily fraction) unless otherwise noted. Vx is the volume of the organ receiving  x Gy. 
Dmax = Maximum radiation dose. 
¶ Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21: 109–122. 
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Table 3. Index results of 2D and 3D margin plans. 
 
Abbreviations: PITV = prescription isodose surface volume to target volume, CI = conformity index, HI = homogeneity index, TCI = target 
conformity index, MHI = modified dose homogeneity index,  CN = conformity number, COSI = critical organ scoring index, QF = quality 
factor, AMF = actual modulation factor, Tx = treatment. 
  2D   3D   
p-value 
  Average standard deviation Average standard deviation 
PITV 0.9976  0.0014  0.9971  0.0013  0.290  
CI 0.9593  0.0012  0.9603  0.0016  0.023  
HI 1.0468  0.0048  1.0475  0.0049  0.450  
TCI 0.9570  0.0012  0.9575  0.0019  0.364  
MHI 0.9774  0.0028  0.9775  0.0032  0.762  
CN 0.9181  0.0019  0.9195  0.0032  0.096  
COSI 0.9254  0.0603  0.8614  0.1520  0.450  
QF 1.0316  0.0086  1.0408  0.0226  0.364  
MU 9728.7  1818.5  11194.6  1711.3  0.076  
Actrual MF 3.7  0.3  3.7  0.3  1.000  
Tx. Time (m) 697.0  128.3  800.6  120.7  0.082  
 16 
Table 4. Dosimetric comparison for OARs between 2D and 3D plan. 
    2D 3D p-value 
    Average (SD) Average (SD) 2D vs. 3D 
Rectum V5 68.02(14.27) 75(12.4) 0.190  
 
V10 60.57(15.34) 68.8(14.2) 0.143  
 
V15 57.22(16.21) 65.6(15) 0.123  
 
V20 54.15(16.64) 62.9(15.6) 0.143  
 
V30 48.66(18.07) 56.1(17.5) 0.190  
 
V50 23.68(12.6) 26.1(13.5) 0.436  
 
V60 8.34(3.46) 8.7(3.7) 0.579  
 
V70 0.21(0.2) 0.2(0.2) 0.739  
 
DMax 70.82(0.84) 70.9(0.7) 0.796  
 
Davg 27.94(8.76) 31.3(8.5) 0.218  
Bladder V5 85.57(28.18) 87.9(25.6) 0.739  
 
V10 80.14(29.51) 85.4(28.4) 0.218  
 
V15 75.97(29.5) 83.4(29.3) 0.165  
 
V20 72.75(29.75) 81.2(30) 0.190  
 
V30 62.04(29.46) 71.7(30.4) 0.315  
 
V50 25(13.67) 27.8(13.9) 0.631  
 
V60 11.31(5.86) 11.8(5.5) 0.739  
 
V70 0.1(0.16) 0.1(0.2) 0.684  
 
DMax 70.75(0.64) 70.8(0.4) 0.912  
 
Davg 32.81(14.32) 37.5(13.5) 0.353  
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Hip Joint V5 92.61(12.17) 96.8(6.2) 0.579  
 
V10 87.65(15.52) 93.1(11.4) 0.165  
 
V15 80.85(18.8) 86.4(16.2) 0.353  
 
V20 62.4(21.72) 67.4(21.6) 0.436  
 
V30 0.286(0.33) 0.3(0.4) 0.971  
 
DMax 30.51(1.38) 30.6(1.0) 0.971  
 
Davg 19.75(3.91) 20.9(3.3) 0.393  
Bone Marrow V5 58.07(18.7) 62.8(19.5) 0.631  
 
V10 51.62(16.64) 56.2(17.9) 0.579  
 
V15 32.74(9.06) 36.3(9.8) 0.280  
 
V20 18.47(6.17) 20.4(6.6) 0.436  
 
V30 5.62(2.59) 6(2.7) 0.529  
 
V50 0.78(0.83) 0.8(0.9) 0.853  
 
V60 0.28(0.5) 0.3(0.6) 0.853  
 
V70 0.04(0.1) 0.1(0.2) 0.971  
 
DMax 64.86(6.34) 65.2(6.2) 1.000  
  Davg 11.32(2.85) 12.2(3.0) 0.529  
Abbreviations: D = dimensional, SD = standard deviation, V5 = volume receiving at least 5 Gy, V10 = volume receiving at least 10 Gy, V15 = 
volume receiving at least 15 Gy, V20 = volume receiving at least 20 Gy, V30 = volume receiving at least 30 Gy, V50 = volume receiving at 
least 50 Gy, V60 = volume receiving at least 60 Gy, V70 = volume receiving at least 70 Gy, Dmax = Maximum point dose, Davg = average dose 
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 Figure Captions. 
Fig. 1. The 2D and 3D margin planning target volumes for prostate cancer planned by 
tomotherapy. a) and b); 2D margin. c) and d); 3D margin. e) and f); 2D and 3D margin. 
Fig. 2. The isodose distributions of axial (a, b), coronal (c, d), and sagittal (e, f); from the 2D 
(left column) and 3D (right column) margin plans for 1 prostate cancer patient. The orange, 
cyan, and blue in the PTV are representative color wash areas of 66.5 Gy (95%), 35 Gy 
(50%), and 21 Gy (30%), respectively.  
Fig. 3. The DVH data from the 2D and 3D margin plans related with Fig. 2.  for 1 prostate 
cancer patient. 
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